Deciphera Pharmaceuticals LLC

148 articles with Deciphera Pharmaceuticals LLC

• Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones

  1/11/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference.

• Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET.

• Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor

  11/30/2020

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients with second-line gastrointestinal stromal tumor (GIST).

• Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/24/2020

  Deciphera Pharmaceuticals, Inc announced that Steve Hoerter, President and Chief Executive Officer, has participated in a fireside chat in advance of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

• The Boston Globe Names Deciphera a Top Place to Work for 2020

  11/23/2020

  Deciphera Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the ​Top Places to Work in Massachusetts in the 13th annual employee-based survey project from ​The Boston Globe.

• Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting

  11/11/2020

  – Preliminary Results Showed 41% (9 of 22 Patients) Objective Response Rate, Including One Confirmed Complete Response – – Treatment was Generally Well-Tolerated with Treatment-Emergent Adverse Events Mostly Grade 1 or 2 – – Based on Preliminary Results, the Expansion Cohorts for DCC-3014 in TGCT Patients Opened at the Recommended Phase 2 Dose of 30 mg Twice Weekly –

• Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting

  11/11/2020

  – Deciphera Presents the First and Largest Baseline Genomic Analysis by Tumor and Liquid Biopsy in Fourth-line Patients with GIST – – Results from an Exploratory Analysis of the Phase 3 INVICTUS Study in Fourth-line GIST Demonstrate the Broad Clinical Activity of QINLOCK Across Mutation Sub-groups –

• Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

  11/10/2020

  Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

• Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results

  11/5/2020

  Marketing Authorisation Application for QINLOCK in Fourth-line GIST Validated by the European Medicines Agency; Commercial Planning for Europe Underway

• Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020

  10/28/2020

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Thursday, November 5, 2020, to discuss the Company’s financial results and provide a corporate update. The conference call may be

• Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

  9/18/2020

  Deciphera Pharmaceuticals, Inc., announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST.

• Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 

  9/17/2020

  - Rebastinib Combined with Paclitaxel Showed Encouraging Preliminary Clinical Benefit and Favorable Tolerability in Patients with Platinum-resistant Ovarian Cancer - - Rebastinib Combined with Carboplatin was Well-tolerated in Patients with Metastatic Solid Tumors and Showed Initial Clinical Activity - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of data from the ovarian

• Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology

  8/17/2020

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine kinase inhibitor, in patients with second-line through fourth-line plus gastrointestinal stromal tumor (GIST).

• 

  FDA Action Alert: Fennec, Gilead/Kite, Deciphera and Jazz/PharmaMar

  8/10/2020

  Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.

• Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference

  8/6/2020

  Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40 th Annual Growth Conference

• Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results

  8/4/2020

  Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments.

• Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020

  7/29/2020

  Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020.

• Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

  7/14/2020

  QINLOCK is the First Approved Tyrosine Kinase Inhibitor Designed Specifically for GIST Regardless of Patients’ Mutational Status

• Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST

  7/2/2020

   Clinically Meaningful Benefit Observed in Patients Receiving QINLOCK Following Progression on Placebo - - Data Featured at the ESMO World Congress on Gastrointestinal Cancer 2020 Virtual Meeting - WALTHAM, Mass.--( BUSINESS WIRE )-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who crossed over t

• Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

  6/22/2020

  QINLOCK Significantly Improved Progression-Free Survival and Showed Clinically Meaningful Overall Survival in Global INVICTUS Phase 3 Study